Erratum: Prescription monitoring programs: Striking the balance between medical use and diver (Journal of Addictions Nursing (2011) 22 (77-82) DOI: 10.3109/10884602.2011.551586);Prescription monitoring programs: Striking the balance between medical use and diversion

Journal of Addictions Nursing

Volumn 22, Issue 1-2, 2011, Pages 77-82

  Fornili, Katherine ^a   Simoni Wastila, Linda ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF NURSING   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79953100684     PISSN: 10884602     EISSN: 15487148     Source Type: Journal    
DOI: 10.3109/10884602.2011.618713     Document Type: Erratum

References (41)

1. Anonymous. (2007). CURES Program [Internet]. Sacramento: Department of Justice, Bureau of Narcotic Enforcement; c2007. Retrieved October 31, 2008, from http://ag.ca.gov/bne/trips.php
2. Anonymous. (2008). The Prescription Form [Internet]: Austin: Texas Prescription Program, Texas Department of Public Safety.
3. APF. (2005). American Pain Foundation (APF) position statement on H.R. 3015 the National All Schedules Prescription Electronic Reporting Act of 2004 (NASPER).
4. ASP. (2008). Alliance for State Pain Initiatives (ASPI). Statement on state prescription drug monitoring programs.
5. CMS. (2008). Deficit Reduction Act: Important Facts for State Policymakers. Retrieved November 11, 2008, from
6. DEA. (2008). Q and A. Prescription drug monitoring programs. Retrieved September 21, 2008, from
7. Fishman, S. (2004). Repeal of triplicate prescribing and the new security paper prescription requirement in California. CSA Bulletin, 46-52.
8. GAO. (1992). Report to the Chairman, Subcommittee on Health, Committee on Ways and Means, House of Representatives. Prescription drug monitoring: states can readily identify illegal sales and use of controlled substances. Retrieved from .
9. Hansen, J. (2002). Prescription drugs: state monitoring programs provide useful tool to reduce diversion. Report to the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives. Retrieved from .
10. Health, N. S. o. D. U. a. (2010). Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings. (No. DHHS Publication No. SMA 10-4856). Rockville, MD: Department of Health and Human Services.
11. Horgan, C., Prottas, J., Tompkins, C., Wastila, L., & Bowden, M. (1993). Summary and conclusions of a review of prescription drug diversion control methods. NIDA Research Monograph, 131, 206-223. (Pubitemid 23303271)
12. Katz, N., Panas, L., Kim, M., Audet, A., Bilansky, A., Eadie, J., et al. (2010). Usefulness of prescription monitoring programs for surveillance-analysis of Schedule II opoid prescription data in Massachusetts, 1996-2006. Pharmacoepidemiology and Drug Safety, 19, 115-123.
13. Keuhn, B. (2007). Opioid prescriptions soar: increase in legitimate use as well as abuse. Journal of the American Medical Association, 297, 249-251.
14. Manchikanti, L., & Singh, A. (2008). Therapeutic opioids: a ten year perspective on the compelxities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician, 11, S63-S88. (Pubitemid 351682079)
15. NASPER. (2005). H.R. 1132 signed by Presdient George W. Bush on 8/11/05. Retrieved November 4, 2010, from
16. NSDOH (2003)Results from the 2002 national survey on drug use and health: National findings No. DHHS Publication No. SMA 03-3836 Rockville MD: Department of Health and Human Services
17. NYSDOH. (1989). Benzodiazepines: prescribing declines under triplicate program. Epidemiology Notes, 4(12).
18. NYSDOH.(1990).Benzodiazepines: additional effects of the triplicate program. Epidemiology Notes, 5(1).
19. NYSDOH 2008 What every practitioner needs to know about controlled substance prescribing Internet: New York State Department of Health
20. ONDCP. (2006). Synthetic National Drug Control Strategy: A Focus on methamphetamine and prescription drug abuse. Retrieved from
21. ONDCP. (March 2008). Current state of drug policy: success and challenges. Retrieved from pdf/successes challenges.pdf Last accessed 1/27/2011.
22. Paulozzi, L., Budnitz, D., & Xi, Y. (2006). Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiology and Drug Safety, 15(9), 618-627. (Pubitemid 44404658)
23. Pearson, S.-A., Soumerai, S., Mah, C., Zhang, F., Simoni-Wastila, L., Salzman, C., et al. (2006). Racial disparities in access following regulatory surveillance of benzodiazepines Archives of Internal Medicine (166).
24. Reisman, R., Shenoy, P., Atherly, A., & Flowers, C. (2009). Prescription opioid usage and abuse relationships: an evaluation of state pescription drug monitoring program efficacy. Substance Abuse: Research and Treatment, 3, 41-51.
25. Ross-Degnan, D., Simoni-Wastila, L., Brown, J., Gao, X., Mah, C., Cosler, L., et al. (2004). A controlled study of the effects of state surveillance on indicators of problematic and non-problematic benzodiazepine use in a Medicaid population. International Journal of Psychiatry in Medicine, 34(2), 103-123. (Pubitemid 39121802)
26. SAMHSA. (2008). Results from the 2007 National Survey on Drug Use and Health: National findings. Retrieved from p0000016.htm.
27. Sigler, K., Guernsey, B., Ingrim, N., Buesing, A., Hokanson, J., Galvan, E., et al. (1984). Effect of triplicate prescription law on prescribing of schedule II drugs. American Journal of Hospital Pharmacy, 41, 108-111. (Pubitemid 14215926)
28. Simeone, R., & Holland, L. (2006). An evaluation of prescription monitoring programs. Retrieved November 4, 2010, from . com/simeone3.pdf
29. Simoni-Wastila, L., Ross-Degnan, D., Mah, C., Gao, X., Brown, J., Cosler, L., et al. (2004). A retrospective analysis of the impact of the impact of the New York triplicate prescription program on benzodiazepine use in Medicaid patients with chronic psychological and neurological disorders. Clinical Therapeutics, 26(2), 322-336. (Pubitemid 38339023)
30. Simoni-Wastila, L., & Tompkins, C. (2001). Balancing diversion control and medical necessity: the case of prescription drugs with abuse potential. Substance Use and Misuse, 36(9 & 10), 1275-1296.
31. TEDS. (2010). Treatment Episode Data Set (TEDS) quick statistics-summary tables. Retrieved November 2, 2010, from webt/teds/tab year.chhose year web table?t state=US
32. Thielke, S., Simoni-Wastila, L., Edlund, M., Martin, B., Braden, J., & Sullivan, M. (2010). Age and sex trends in long-term opioid use in two large American health systems between 2000 and 2005. Pain Medicine, 11, 248-256.
33. Twillman, R. (2006). Impact of prescription monitoring programs on prescription patterns and indicators of opioid abuse. Journal of Pain, 7, S6.
34. USDOJ. (2010). Harold Rogers Prescription Drug Monitoring Program. Retrieved November 4, 2010, from
35. Wagner, A., Soumerai, S., Zhang, F., Mah, C., Simoni-Wastila, L., Cosler, L., et al. (2003). Effects of state surveillance on new post-hospitalization benzodiazepine use. International Journal of Quality in Health Care, 15(5), 423-431. (Pubitemid 37259379)
36. Wang, J., & Christo, P. (2009). The influence of prescription monitoring programs on chronic pain management. Pain Physician, 12, 507-515.
37. Warner, M., Chen, L., & Makuc, D. (2009). Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006. (No. NCHS data brief, no. 22). Hyattsville, MD: Department of Health and Human Services.
38. Wastila, L., & Bishop, C. (1996). The influence of multiple copy prescription programs on analgesic utilization. J Pharm Care Symptom Control, 4(3), 3-19. (Pubitemid 26381581)
39. Weintraub, M., Singh, S., Byrne, L.,Maharaj, K.,&Guttmacher, L. (1991).Consequences of the 1989 New York state triplicate benzodiazepine prescription regulations. JAMA, 266(17), 279-293. (Pubitemid 23303282)
40. White, A.G., Birnbaum, H.G., Mareva, M., Vallow, S., Schein, J., & Katz, N. (2005). Direct costs of opioid abuse in an insured population in the United States. Journal of Managed Care Pharmacy, 11(6), 469-479.
41. Zerzan, J., Morden, N., Soumerai, S., Ross-Degnan, D., Roughead, E., Zhang, F., et al. (2006). Trends and geographic variation of opiate medication use in state Medicaid fee-for-service programs. Medical Care, 44(11), 1005-1010. (Pubitemid 44674032)